TBK1 and obesity disorder: Moreover, amlexanox, a specific inhibitor of TBK1/IKKɛ, has been shown in other trials to be a prospective medicine of choice for the treatment of inflammation-related illnesses such as liver fibrosis and damage, type 2 diabetes, and obesity-related metabolic dysfunction19–22.